Characteristics of patients initiating teriparatide for the treatment of osteoporosis

被引:14
|
作者
Foster, S. A. [1 ]
Foley, K. A. [2 ]
Meadows, E. S. [1 ]
Johnston, J. A. [1 ]
Wang, S. [2 ]
Pohl, G. M. [1 ]
Long, S. R. [2 ]
机构
[1] Eli Lilly & Co, Lilly Corp Ctr, Indianapolis, IN 46285 USA
[2] Thomson Medstat, Ann Arbor, MI USA
关键词
bisphosphonates; demographics; osteoporosis; teriparatide; treatment;
D O I
10.1007/s00198-007-0455-4
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The demographic and clinical characteristics of patients initiating teriparatide were compared with those of patients initiating bisphosphonates for the treatment of osteoporosis. In these samples of commercially insured, Medicare, and Medicaid patients, patients initiating teriparatide were older, in poorer health, and appeared to have more severe osteoporosis than patients initiating bisphosphonates. Introduction The demographic and clinical characteristics of patients initiating teriparatide are compared with those of patients initiating bisphosphonates. Methods Beneficiaries (45 years and older) with at least one claim for teriparatide or a bisphosphonate from 2003 to 2005 and continuous enrollment in the previous 12 months and subsequent 6 months were identified from commercial, Medicare, and Medicaid administrative claims databases. Patients initiating teriparatide (commercial/Medicare (N=2,218); Medicaid (N=824)) were compared to patients initiating bisphosphonates (commercial/Medicare (N=97,570); Medicaid (N=77,526)) in terms of age, provider specialty, comorbidities, prior use of osteoporosis medications, fractures, BMD screening, health status, and resource utilization. Results Teriparatide patients were older and in poorer health than bisphosphonate patients. Approximately 38% of teriparatide patients in both groups had fractured in the pre-period compared to 16% of commercial/Medicare and 15% of Medicaid bisphosphonate patients. Teriparatide patients were more likely to have used osteoporosis medications in the pre-period (79.9% versus 32.1% (commercial/Medicare); 82.2% versus 19.6% (Medicaid)). Conclusions In these samples of patients, those initiating teriparatide differed from those initiating bisphosphonates. Teriparatide patients were older, in poorer health, and appeared to have more severe osteoporosis than bisphosphonate patients. Comparisons of treatment outcomes should take these differences in patient characteristics into consideration.
引用
收藏
页码:373 / 377
页数:5
相关论文
共 50 条
  • [41] Safety and efficacy of teriparatide treatment for severe osteoporosis in patients with Duchenne muscular dystrophy
    Nasomyont, N.
    Keefe, C.
    Tian, C.
    Hornung, L.
    Khoury, J.
    Tilden, J.
    Hochwalt, P.
    Jackson, E.
    Rybalsky, I.
    Wong, B.
    Rutter, M.
    [J]. NEUROMUSCULAR DISORDERS, 2020, 30 : S132 - S132
  • [42] Safety and efficacy of teriparatide treatment for severe osteoporosis in patients with Duchenne muscular dystrophy
    Nasomyont, N.
    Keefe, C.
    Tian, C.
    Hornung, L.
    Khoury, J.
    Tilden, J. C.
    Hochwalt, P.
    Jackson, E.
    Rybalsky, I
    Wong, B. L.
    Rutter, Meilan M.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2020, 31 (12) : 2449 - 2459
  • [43] Pain reduction after treatment with teriparatide in 33 patients affected by severe osteoporosis
    Massafra, U.
    Martin, L. S.
    Ragno, A.
    Migliore, A.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2007, 18 : S86 - S86
  • [44] EVALUATION OF THE PAIN INTENSITY AND QUALITY OF LIFE OF PATIENTS WITH OSTEOPOROSIS DIAGNOSIS AND TERIPARATIDE TREATMENT
    Pinzon, A.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2018, 29 : S518 - S519
  • [45] Safety and efficacy of teriparatide treatment for severe osteoporosis in patients with Duchenne muscular dystrophy
    N. Nasomyont
    C. Keefe
    C. Tian
    L. Hornung
    J. Khoury
    J. C. Tilden
    P. Hochwalt
    E. Jackson
    I. Rybalsky
    B. L. Wong
    M. M. Rutter
    [J]. Osteoporosis International, 2020, 31 : 2449 - 2459
  • [46] DAILY TERIPARATIDE TREATMENT AFTER BISPHOSPHONATE THERAPY IN OSTEOPOROSIS OF PATIENTS WITH RHEUMATOID ARTHRITIS
    Hirano, Y.
    Isono, M.
    Fukui, J.
    Hasegawa, J.
    Ishiguro, N.
    Kojima, T.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 368 - 369
  • [47] ADHERENCE IN PATIENTS WITH SEVERE OSTEOPOROSIS TREATED WITH TERIPARATIDE
    Ziller, V.
    Zimmermann, S-P.
    Ziller, M.
    Hadji, P.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2009, 20 : 34 - 34
  • [48] Persistence with teriparatide in patients with osteoporosis: the UK experience
    Arden, N. K.
    Earl, S.
    Fisher, D. J.
    Cooper, C.
    Carruthers, S.
    Goater, M.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2006, 17 (11) : 1626 - 1629
  • [49] Occurrence of hypercalciuria in patients with osteoporosis treated with teriparatide
    Miller, Paul D.
    Bilezikian, John P.
    Diaz-Curiel, Manuel
    Chen, Peiqi
    Marin, Fernando
    Krege, John H.
    Wong, Mayme
    Marcus, Robert
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2007, 92 (09): : 3535 - 3541
  • [50] Persistence with teriparatide in patients with osteoporosis: the UK experience
    N. K. Arden
    S. Earl
    D. J. Fisher
    C. Cooper
    S. Carruthers
    M. Goater
    [J]. Osteoporosis International, 2006, 17 : 1626 - 1629